A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Latiglutenase (Primary)
  • Indications Coeliac disease
  • Focus Therapeutic Use
  • Acronyms CeliAction
  • Sponsors Alvine Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2017 Data published in an ImmunogenX Media Release.
    • 28 Jul 2017 Results of a post hoc subgroup analysis published in the Digestive Diseases and Sciences
    • 09 May 2017 Results of subgroup analysis assessing effect of latiglutenase on specific symptoms of Coeliac-disease, presented at the Digestive Disease Week 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top